Proteomics International Laboratories Ltd.ASX: PIQ

A landmark in non-invasive Esophageal Cancer diagnosis

· Issued by Proteomics International Laboratories Ltd.

Filed with ASX · · 5 pages · English

Summary by 6ix AI

Proteomics International Laboratories Ltd. has announced the publication of clinical validation results for its PromarkerEso blood test, which can diagnose esophageal adenocarcinoma with high accuracy. The test demonstrated strong sensitivity and specificity in a study involving multiple patient cohorts, marking a significant advancement in non-invasive cancer diagnostics. Commercialization of PromarkerEso in Australia is expected soon, with plans to expand into other markets.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Proteomics International Laboratories Ltd. on 6ix

Story so far

Earlier from Proteomics International Laboratories

Later from Proteomics International Laboratories

All Proteomics International Laboratories news releases